Trial Profile
Phase 1, Dose Escalation Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Figitumumab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Biomarker
- Sponsors Pfizer
- 15 Jul 2009 Actual patient number (19) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 15 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.